Samumed Begins Phase 3 Lorecivivint (SM04690) Trial of Regenerative Therapy for Knee Osteoarthritis, Following Success of Phase 2 Trial

Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical program of lorecivivint (SM04690) for the treatment of knee osteoarthritis (OA), which will observe the effects of lorecivivint on patient-reported outcomes and disease progression. The program will be referred to as STRIDES. Lorecivivint is a disease modifying drug that targets the WNT pathway. In the...

Pentosan Polysulfate arthritis treatment launched for dogs – humans next?

Finally, Pentosan Polysulfate is getting the attention it deserves. This drug was invented in the 1940's and has been used for interstitial cystitis, thrombi, and experimentally, Creutzfeldt–Jakob disease, and various other infectious diseases. The chondroprotective ( cartilage protecting ) aspects of this drug have been known since the 1980's, and only recently did a few pharmaceutical companies decide to take...

Paradigm’s Phase IIb trial of Sodium pentosan polysulfate for knee osteoarthritis shows excellent results

Paradigm Pharmaceutical has shown some impressive results in reducing bone marrow lesions and reducing pain in a phase 2b trial of their re-commercialized drug, Sodium Pentosan Polysulfate ( SPP ). We covered SPP in a previous article, but here's a quick wrap up: SPP was invented in the 1940’s and has been used for interstitial cystitis, thrombi, and...

The Invossa rollercoaster continues; class action lawsuit started; critics claim the arthritis treatment is ineffective

There has been a flurry of reports from South Korean news outlets relating to the Invossa GP-293 cell mislabeling incident, and this article is meant to be a summary of those reports. Kolon Life Science is being sued Oh Kims Law & Company has started a class action lawsuit against Kolon Life Sciences over injections of...

Medivir’s MIV-711 therapy for osteoarthritis shows disease modifying activity in phase 2 extension trial

Medivir presented the data on their Cathepsin K Inhibitor, MIV-711, at the OARSI conference over the weekend, and the results were a bit of a mixed bag but generally positive. Most therapies that regenerate cartilage and/or bone consist of single or multiple injections into the affected joint, and are long acting. Many of these therapies use growth factors, stem cells,...

Cartilage Regenerating therapy, Invossa, pulled from market despite lack of evidence of harm

The health authorities canceled the license for Kolon Life Sciences' osteoarthritis gene therapy drug Invossa, Tuesday, over the mislabeling of a key ingredient. In addition, they have decided to pursue criminal charges against the pharmaceutical firm.Invossa was the first regenerative gene therapy drug for patients with the degenerative joint disease. The Ministry of Food and Drug Safety approved it use in Korea...

Kolon confirms existence of questionable GP-293 cells in cartilage regenerating drug, Invossa. Regulatory approval up in the air

The punches keep coming for Kolon Life Science. Not only has their breakthrough cartilage regrowth drug, Invossa, been suspended from sale in their home market of South Korea, but they have also confirmed the existence of GP-293 cells in their most recent batch of the drug. GP-293 cells are derivatives of HEK-293 cells. HEK-293 cells are well known to differentiate...
Invossa Vials

Invossa has lost it’s regulatory approval in South Korea

Today, Kolon Life Sciences ordered an emergency stop-sale on distribution and sales of their pioneering cartilage regeneration drug, Invossa. KLS CEO Lee Woo-suk held a press conference explaining the reason for the temporary withdrawal - an ingredient in Invossa's formulation was mislabeled as originating from a chondrocyte cell, instead of a kidney cell. This discrepancy...